Quantum BioPharma Files Reply and Provides Update on Court Case Seeking Damages Against CIBC, RBC and Others in Excess of $700,000,000 USD for Possible Stock Price Manipulation/Spoofing
This is Quantum's response to a memorandum of law that CIBC and RBC filed on June 16, 2025, in support of a joint motion to dismiss the Amended Complaint filed by Quantum BioPharma on May 31st, 2025. The amendment complaint filed by Quantum BioPharma allege that CIBC World Markets, RBC Dominion Securities, and others (the 'Defendants') engaged in market manipulation schemes that violated Section 10(b) and Rule 10b-5(a) and (c) and Section 9(a) of the Securities Exchange Act of 1934. This lawsuit alleges that between 1st of January 2020, and 15th of August 2024 the Defendants and/or their customers used 'spoofing' techniques to manipulate the share price of Quantum BioPharma shares. Quantum is seeking damages of more than $700 Million USD.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
4 hours ago
- Globe and Mail
CVRx (CVRX) Q2 Revenue Jumps 15%
Key Points Revenue (GAAP) rose 15% to $13.6 million, surpassing both company expectations and analyst estimates. Net loss narrowed on a per-share basis to $(0.57) (GAAP), primarily due to a higher share count despite a slight increase in overall losses. These 10 stocks could mint the next wave of millionaires › CVRx (NASDAQ:CVRX), a medical device innovator focused on heart failure therapy, released its second quarter 2025 earnings on August 4, 2025. The most important news was a Revenue (GAAP) increased to $13.6 million, up 15% year-over-year and above analyst expectations of $13.29 million (GAAP). The company also reported a net loss of $14.7 million, or $(0.57) per share (GAAP). While that loss widened slightly, the per-share figure (GAAP) improved due to an increased share count. The quarter reflected strong commercial progress for its Barostim neuromodulation device despite heavy investment in sales and marketing. Results slightly exceeded internal and external expectations, and management narrowed its revenue guidance to a range of $55.0 million to $57.0 million. Metric Q2 2025 Q2 2025 Estimate Q2 2024 Y/Y Change EPS (GAAP) $(0.57) $(0.52) $(0.65) 12.3% Revenue (GAAP) $13.6 million $13.29 million $11.8 million 15.1% Gross Profit $11.5 million N/A N/A Gross Margin 84% 84% 0% Net Loss $14.7 million $14.0 million -5.0% Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. About CVRx and Its Core Business CVRx (NASDAQ:CVRX) specializes in developing implantable medical devices for treating heart failure. Its leading product, Barostim, is a neuromodulation device—meaning it delivers targeted electrical pulses to nerves in the carotid artery to improve function of the autonomic nervous system. This system regulates key bodily functions, including blood pressure and heart rate. Barostim is designed to treat patients with heart failure with reduced ejection fraction (HFrEF), providing an option that avoids direct implantation in the heart. The company's commercial priorities are building deep adoption in centers with strong heart failure programs and expanding reimbursement pathways to improve access. Solid clinical evidence and reliable regulatory support have been the company's main success factors, along with educating physicians and patients on Barostim's benefits. Quarter Highlights and Key Developments During the period, total revenue (GAAP) reached $13.6 million, outpacing both the company's guides and Wall Street expectations by over 2%. U.S. heart failure revenue remained the largest contributor, climbing to $12.1 million, with units up to 387 from 339 in the prior year. U.S. sales overall were $12.2 million, also up 15% (GAAP). Across the Atlantic, European revenue grew 19% to $1.3 million (GAAP), but the number of European implant units declined from 63 to 61, signaling some softness in procedural volume despite improved pricing or product mix. Active implanting centers in the U.S. grew to 240, reflecting 13 new centers added in the U.S. during the quarter. U.S. sales territories also grew to 47, up from 45, while European territories held steady at five. U.S. revenue accounted for approximately 89.8% of total sales (GAAP), indicating the company's primary growth engine remains domestic. The company attributes revenue gains to both new account additions and greater utilization per center, while the slightly lower European volumes point to variability in adoption across geographies. Gross profit (GAAP) grew 16% from the prior year, maintaining a gross margin of 84%. On the expense side, research and development (R&D) spending declined 11% to $2.5 million, reflecting lower compensation as resources shifted toward commercial growth. Selling, general, and administrative (SG&A) costs (GAAP) increased 11% to $23.4 million, driven mainly by higher employee compensation, travel, and non-cash stock-based grants, with some relief from lower advertising costs. The higher SG&A, while outpaced by revenue growth, resulted in operating and net losses that remain substantial—operating loss (GAAP) at $14.4 million and net loss (GAAP) at $14.7 million. Multiple reimbursement milestones provided stability for Barostim's future. The Centers for Medicare & Medicaid Services (CMS) proposed to retain Barostim as a covered outpatient procedure at the $45,000 payment level, removing some uncertainty for hospitals and ensuring continued access. In addition, CMS proposed favorable physician payment levels of about $550 for new procedure coding effective in 2026. On the clinical front, highlighted real-world data presented at major cardiology conferences showed large reductions in heart failure hospital visits—down 85% for heart failure, 84% for cardiovascular causes, and 86% for all causes—after Barostim implantation, based on comparisons of hospital visits for 306 Barostim patients in the 12 months prior to implant and an average of almost two years post-implant. These real-world results have been well received by physicians and payers, which it views as an important driver of payer support and future uptake. Furthermore, the company is preparing a large pragmatic randomized controlled trial (RCT), potentially enrolling up to 2,000 patients, to further establish Barostim's efficacy, as discussed in recent management commentary. Although the timing and costs of that effort depend on regulatory approval and payer support, management sees it as a long-term enabler of broader use. The company finished the quarter with $95.0 million in cash and cash equivalents, down from $105.9 million at year end 2024. Net cash used for operations and investing was $8.0 million, showing some improvement from $10.2 million a year ago, but still indicating ongoing cash burn. Long-term debt remained steady at $49.4 million. Looking Ahead: Guidance and Watch Items For fiscal 2025, management narrowed its revenue guidance to $55.0–$57.0 million, tightening the prior range and signaling increased confidence from better visibility into commercial results. The company expects gross margin to remain high at 83–84%. Operating expenses are now projected at $96.0–$98.0 million, a slight increase at the midpoint, reflecting ongoing investments in sales and account growth. Revenue is expected in the range of $13.7–$14.7 million for the next quarter, suggesting continued double-digit revenue growth ahead, as evidenced by a 15% year-over-year increase. Areas to watch in the coming quarters include progress in adding new implanting centers, the effectiveness and productivity of the enlarged sales force, and movement toward scaling revenues faster than expenses. Investors will also monitor any shift in European procedure volumes, cash usage trends, and the company's progress on the planned large RCT, as this trial could both validate Barostim's utility and expand the addressable market if successful. CVRX does not currently pay a dividend. Revenue and net income presented using U.S. generally accepted accounting principles (GAAP) unless otherwise noted. Where to invest $1,000 right now When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor's total average return is 1,019%* — a market-crushing outperformance compared to 178% for the S&P 500. They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor. See the stocks » *Stock Advisor returns as of August 4, 2025
Globe and Mail
7 hours ago
- Globe and Mail
No Pain, No 100,000% Gain
Since David Gardner's initial Nvidia (NASDAQ: NVDA) recommendation on April 15, 2005, a passive S&P 500 index investor could have enjoyed a 726% return simply by reinvesting dividends. But that 2005 rec, now Stock Advisor 's all-time top performer, leaves the market in the dust with a return of 107,479% as of this writing. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More » That is not a typo. Nvidia is the first Stock Advisor pick to grow more than 1,000 times in value! While it's easy to highlight a winner, the real challenge was having the patience to hold Nvidia shares through every bout of uncertainty over the years. What lessons could we learn from the most successful outlier in our flagship service? Quite a few. Despite its impressive returns, holding onto Nvidia wasn't a walk in the park. Let's explore what it truly takes to achieve a 1,000x return. At a Glance The Good The Bad The Ugly The Foolish Bottom Line The Good A Stock That Has Doubled 10 Times The Rule of 72 is a simple way to estimate how long it takes for an investment to double. If a stock grows 9% a year, roughly the historical return of the stock market, it would take eight years (72 / 9) to double an investment. Now, imagine your favorite stocks are horses running a race around a track. Each time they complete a lap, they double in value. Knowing that the stock market as a whole might take nearly a decade to double, which horses would you bet on? In this race, the horses don't stop running, and you can choose to back those clearly leading the pack -- including Nvidia, which has now finished 10 laps of doubling since 2005, with 9 of those laps taking 2.5 years or less. Lap Multiple Achieved Month Started Months to Complete 1 2x April 2005 9 2 4x Jan. 2006 17 3 8x June 2007 109 4 16x July 2016 5 5 32x Dec. 2016 13 6 64x Jan. 2018 30 7 128x July 2020 13 8 256x Aug. 2021 22 9 512x June 2023 9 10 1,024x March 2024 16 Many investors might have hesitated to buy Nvidia, waiting for a pullback after seeing it double time and again. However, those who waited often found themselves still sidelined, missing out on its phenomenal growth. Anchoring to past prices is common, but in this endless race, wouldn't you prefer to back the horse consistently lapping the field? As David Gardner wisely notes, five harmful words for investors are, "I guess I missed it." The next doubling for Nvidia would require another $4 trillion in value, a feat that might not seem as far-fetched in the future. Excluding PetroChina 's brief brush with a trillion-dollar valuation in 2007, Apple (NASDAQ: AAPL) founded the trillion-dollar club in August 2018 before reaching the $2 trillion and $3 trillion thresholds in 2020 and 2023, respectively. Nvidia broke the $4 trillion barrier earlier in July, with Microsoft (NASDAQ: MSFT) joining on Wednesday. There's no guarantee that Nvidia will ever get to $8 trillion or $16 trillion -- let alone get there first -- but it does have the inside lane. More Years of Doubling Than Down Years One fun stat I've stumbled upon while following Nvidia comes courtesy of a website listing calendar-year returns as well as pre-split pricing (which I'll mention again later). Including the partial year of its 1999 IPO, Nvidia has enjoyed 10 calendar years with gains of 100% or more, while the stock fell by any amount in only 7 years so far. 1999, 2001, 2003, 2006, 2009, 2016, 2020, 2021, 2023, 2024 2002, 2008, 2010, 2011, 2012, 2018, 2022 Nvidia isn't unique in this category -- Shopify (NASDAQ: SHOP) and The Trade Desk (NASDAQ: TTD) share the same distinction of having more years of 100% gains than of losses for now -- but it's noteworthy. The Winner Outweighing All the Losers Stock Advisor members have access to our complete scorecard, where each recommendation is tracked against the S&P 500 from the time it's selected until it's sold (or held through today). With two stock picks each month since 2002, we've seen hundreds of winners and losers along the way. Data Source: The Motley Fool. Returns as of July 29, 2025. Graphic: Rik Silverman. This graphic illustrates the returns of all 562 Stock Advisor recommendations relative to their S&P 500 benchmark. David's April 2005 Nvidia selection leads with more than 106,000 percentage points of outperformance above the market's 726% return in the same period. Not all underperformers lost value; some, like FedEx 's (NYSE: FDX) 403% gain since 2003, underwhelmed compared to the S&P's 959% over the same time frame. One standout like Nvidia can outweigh all the underperformers in Stock Advisor 's storied history. David's 2009 Nvidia rerecommendation, along with two long-standing Netflix (NASDAQ: NFLX) recommendations, further highlights this point. But it gets better: The gain on the initial rec since April 15, 2025 -- the compounding just after the 20th anniversary -- nearly makes up for the hundreds of losing stock picks over the years. Nvidia exemplifies the Foolish principle of holding winners and not selling too early. Yet its journey wasn't always smooth. A stock that seems today to be taking a long victory lap once appeared to be slowly circling the drain. The Bad The Stock That Plummeted 85% Imagine a stock falling 80%. It might invoke thoughts of high-growth investments facing challenges or an unfavorable interest rate climate, perhaps echoing bad memories of 2021 or 2022. If you remember the 2000s, you might recall that something big happened in the market before the end of the decade. The first Nvidia rec quintupled by 2007 only to lose all those gains in mere months. Data Source: Yahoo Finance. Returns as of July 29, 2025. Graphic: Rik Silverman. If it needs to be repeated, this is a chapter in the greatest stock story of the last 20 years. The 85% plummet was the steepest for Nvidia shares since 2005, but seeing it trade significantly below previous highs was common for shareholders over the last 20-odd years. On average, Nvidia spent its time on our scorecard 34% below its then-highs. If we count days on which the stock closed more than 20% below its historic high price, Nvidia was in its own bear market more than 59% of the time! Let that marinate for a moment. We all wish for a time machine so we could go back and buy Nvidia stock decades in the past. But if you had owned shares at that time, would you honestly have held through to today? After all, the discomfort wasn't limited to the sharp pangs of these low points. There was also a dull pain that lasted for years. The Lost Decade On October 17, 2007, Nvidia closed at an all-time high. The next day, shares declined, and the record high was not reset until May 15, 2016. There's a reason the Fool encourages investors to hold stocks for five years or more. Periods of volatility or apparent mispricing can persist much longer than most investors (and all traders) are willing to wait. Could you sit on your hands while a stock was 85% underwater after six months or 50% in the red after the better part of a decade, waiting like a good Foolish investor should? And after all of those years waiting to break even, would you cut ties as soon as shares rose in spring 2016 back to prices of more than eight years earlier? If that sounds like something you might have done, I have some bad news. Guess which Fool rec was the best-performing stock in the entire S&P 500 in 2016? That would be Nvidia, of course, the dog many investors sold along the way. It gained 227% that year, before David recommended it for a third time in January 2017. The Ugly Holding Leads to Portfolio Concentration Nothing is quite as unpleasant as several years of dismal returns, but what differentiates Foolish investing outcomes is often a willingness to sit in your own discomfort and build the long-term-investor mindset when the short run looks bleak. That involves challenging conventional wisdom. I suspect most investors wouldn't believe the following: A large cap worth $40 billion in 2016 could grow 100x in the next nine years. A mega cap worth $400 billion in 2022 could grow 10x in just three years. An investor who sold at the 2007 peak and who successfully avoided the 85% drop would have missed out on 17,660% gains if they stayed on the sidelines. An investor who locked in gains by selling half their position when Nvidia first doubled and stayed in with "house money" has now given up 54,689% of the gains they could have earned. The greatest mistake we make as investors is selling our winners too early. The opportunity cost of those mistakes compounds over time as well, but that doesn't mean you should never sell. While the pullback in Nvidia's stock price during the great financial crisis was much deeper from prior highs than any drop since, relatively smaller recent drawdowns had much larger dollar impacts for anyone who has held many years. The 37% pullback between January and April meant that the earliest Nvidia rec dropped from being a 910-bagger to a 574-bagger, temporarily losing 336 times an original investment. We know now that Nvidia went on to greater heights within months, but a concentrated position without any allocation guardrails would have become a major risk. You have more flexibility to set your own sleep number and trim overweight positions than the Stock Advisor team has on our scorecard. It's possible that we could someday keep Nvidia as a high-conviction buy recommendation while at the same time closing one or two of the active recs as a reminder of prudent portfolio management rather than as a statement of near-term outlooks or overvaluation. The Thesis Had to Evolve In the 1990s, our Chief Rule Breaker actually rooted against Nvidia, seeing it as a rival to his preferred video game graphics card company, 3Dfx. By 2005, Nvidia had acquired 3Dfx, and David's investment thesis focused on Nvidia's growth potential with Microsoft's Xbox and Motorola (NYSE: MSI) cellphones. Cloud computing and data centers, now Nvidia's largest business segment, were nonexistent. Cryptocurrency mining hadn't been invented yet, and artificial intelligence was absent from the original vision. Even CEO Jensen Huang's enduring leadership wasn't part of David's initial analysis. While some investment theses remain straightforward -- perhaps selling more shoes or opening more coffee shops -- the biggest winners have a quality we call optionality. You might foresee that an online bookseller like Amazon (NASDAQ: AMZN) could become "the everything store" or that Netflix could pivot from mailed DVDs to video streaming. It's crucial to look ahead, acknowledging that successful investments might differ greatly from their original business models. But reevaluating your understanding of your investments is easier said than done, and it might take some extra homework to stay comfortable holding onto developing winners. The Penny Stock That Wasn't Nvidia's 2005 cost basis on our scorecard is just $0.16, at least until it's adjusted further lower due to dividends or future stock splits. One of the biggest mistakes new investors often make is to see data like this and presume the only place to hunt for multibaggers is among penny stocks. The reason for that misdirection is stock splits. Nvidia has never traded in penny-stock territory since 2005 due to four splits: April 2006: 2-for-1 split September 2007: 3-for-2 split July 2021: 4-for-1 split June 2024: 10-for-1 split If you followed the April 2005 recommendation, an investment of less than $20 per share would now translate to 120 shares for every 1 held since then. Without these splits, that single share would today be worth above $21,000. Nvidia would have the same market cap but far fewer shares outstanding. While fractional shares weren't available back then, today's investors can buy partial shares of many companies through their broker for as little as $5. For the same dollar amount invested, I'd rather own a fraction of a strong business like Nvidia than thousands of shares of a failing one trading over the counter for pennies. The Foolish Bottom Line Nvidia has been a mainstay on Stock Advisor 's Foundational Stocks list since 2022 and is likely to remain a Fool favorite for years to come. If you don't own shares directly, know that almost $8 out of every $100 invested in an S&P index fund is tied to Nvidia, its largest weight today. And those who have followed our recommendation for years might own more than enough already, which shifts the question of whether to buy to when to pare down an oversize position in the years ahead. (That's how I'm thinking through the 70x gains on the first block of shares I bought in 2017.) As I wrote above, there's no guarantee Nvidia will continue to be the market darling it has been for so long. But if there's one idea I would take to the bank -- one premise I'm nearly certain about -- it's that Nvidia isn't done teaching Fools lessons about long-term thinking that will pay dividends across all the other investments we consider on our investing journeys. If you haven't held Nvidia since 2005, it's not too late to collect a small slice of one of the highest-quality businesses in the world. And if you have... take that victory lap. You've earned it. Further Reading A Motley Fool Co-Founder's Roller-Coaster Nvidia Story by David Gardner, 1/29/2024 * When Hunting for Outliers Makes All the Difference by Loren Horst, 8/25/2023 * The Best Problem to Have by Loren Horst, 3/10/2020 * The Agony of High Returns by Morgan Housel, 2/9/2016 David's Top Pick: Nvidia by David Gardner, 4/15/2005 *Accessible to Motley Fool Stock Advisor members. Should you invest $1,000 in Nvidia right now? Before you buy stock in Nvidia, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Nvidia wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $624,823!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,064,820!* Now, it's worth noting Stock Advisor's total average return is 1,019% — a market-crushing outperformance compared to 178% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025 Loren Horst has positions in Amazon, Nvidia, Shopify, and The Trade Desk. The Motley Fool has positions in and recommends Amazon, Apple, Booking Holdings, FedEx, Microsoft, Netflix, Nvidia, Shopify, and The Trade Desk. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy.
Globe and Mail
7 hours ago
- Globe and Mail
Should You Buy Nvidia Stock Before Aug. 27? Here's What the Evidence Suggests.
Key Points After more than two years of phenomenal gains, investors are wary about the future of AI. Nvidia's GPUs are a staple in the AI revolution, and sales continue at a brisk pace. There's a growing body of evidence that suggests Nvidia's epic run will continue, as will the stocks volatility. 10 stocks we like better than Nvidia › The dawn of artificial intelligence (AI) in late 2022 has had a profound impact on the technology landscape. The initial fervor has since died down, and investors are looking for compelling evidence that the adoption of AI has room to run. Nvidia (NASDAQ: NVDA) graphics processing units (GPUs) were widely adopted and have become the gold standard for generative AI. The company is scheduled to release the results of its fiscal 2026 second quarter after the market closes on Wednesday, Aug. 27, and Wall Street and shareholders alike will be sitting on the edge of their seats looking for clues that strong demand for AI chips continues. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » Let's look at the company's most recent results, what current events suggest about the future, and determine if Nvidia stock still represents a compelling opportunity heading into the company's highly anticipated financial report. Remarkable results After generating triple-digit revenue and profit growth for two consecutive fiscal years, growth inevitably slowed, and investors got the jitters. Despite tough year-over-year comps, Nvidia's results were still enviable. For its fiscal 2026 first quarter (ended April 27), Nvidia reported record revenue of $44.1 billion, which soared 69% year over year and 12% sequentially. This resulted in adjusted earnings per share (EPS) of $0.81, up 33%, but there's an asterisk on those numbers. Nvidia took a $4.5 billion writedown on H20 chips destined for China, because of the Trump administration's moratorium on AI chip sales in that country (which has since been lifted). Without that charge, EPS would have been $0.96, a 57% increase. Make no mistake: It was the continuing adoption of AI that drove the robust results, as revenue from Nvidia's data center segment climbed 73% to $39 billion, representing 89% of its total revenue. Management expects Nvidia's growth spurt to continue, albeit at a more moderate pace. For its fiscal 2026 second quarter (ended July 27), management is guiding for revenue of $45 billion, which would represent year-over-year growth of 50%. Wall Street is equally bullish, with analysts' consensus estimates calling for revenue of $45.68 billion and adjusted EPS of $1.00. While this would represent a minor slowing compared with last quarter's robust growth, it would still be remarkable nonetheless. Same customers, expanding opportunity The biggest concern among Nvidia investors is that the adoption of AI will hit a wall, but there's simply no evidence to back that assertion. In fact, all the available evidence suggests the proliferation of AI continues. Amazon Web Services, Microsoft Azure, and Alphabet 's Google Cloud, are collectively known as the "Big Three" in cloud computing, and each has recently revealed plans to increase infrastructure spending this year, beyond the already robust spending that was previously announced. Furthermore, most of that spending will be allocated to additional data centers to support the growing demand for AI -- most of which will run on Nvidia GPUs. In addition, Meta Platforms also announced that it was increasing its capital expenditure spending plans for the year. The totals are enlightening: Amazon: $118 billion, up from $100 billion. Microsoft: $100 billion, up from $80 billion. Alphabet: $85 billion, up from $75 billion. Meta: $69 billion, up from $62.5 billion. It's no coincidence that these four companies are also Nvidia's biggest customers. Add to that the resumption of H20 chip sales and China, and it appears clear that Nvidia's AI opportunity continues to expand. Should you buy the stock before Aug. 27? To be clear, I expect Nvidia stock to remain volatile, driven by the inevitable ebbs and flows of AI spending. That said, its success thus far has been undeniable. Over the past three years, the stock has gained 882% (as of this writing) but has also fallen as much as 37% -- so it isn't for the faint of heart. This helps illustrate one of the hallmarks of investing success: Treat buying stocks as partial ownership in a business, own stocks in the best companies out there, and commit to holding for at least three to five years. That takes us back to the main question: Should you buy Nvidia stock before Aug. 27? The unspoken question here is whether Nvidia stock will be up or down following the release of its highly anticipated quarterly report. Truth be told, I have no idea, nor does anyone else for that matter. My crystal ball has been on the blink for some time, but if I were in the mood to prognosticate, I would feel comfortable making several very vague predictions: Nvidia will announce yet another in a long and growing series of quarterly revenue records. Given the company's track record of exceeding expectations, I suspect it will beat analysts' consensus estimates, which are calling for sales of $45.68 billion -- which is slightly ahead of management's guidance of $45 billion -- and adjusted EPS of $1.00. Beyond that, it's anyone's guess, and my predictions could be way off base. That said, I'm still extremely confident that my investing thesis for Nvidia remains intact. The company's cutting-edge GPUs are still the gold standard, driving the AI revolution, and rivals have yet to challenge its position as the undisputed market leader or come up with a superior product. The specter of competition remains, as there's always the possibility that a technological innovation could steal Nvidia's thunder. Most experts agree that it's still early innings for AI, but there's no consensus about the size of the market. Even the most conservative estimates start at $1 trillion. Big Four accounting firm PwC estimates the total economic impact at $15.7 trillion between now and 2030. The truth is nobody knows for sure. Nvidia stock is currently selling for roughly 30 times next year's earnings. However, that premium is backed by the company's track record of innovation, industry-leading position, and history of growth. This underpins my confidence that the runway ahead is long. For those who believe that the AI revolution will play out over the next decade and Nvidia will maintain its position as the leading provider of AI chips, the answer is clear. We don't know what the stock will do between now and Aug. 27 and for long-term investors, that doesn't matter. We'll simply buckle up for the bumpy (and profitable) ride ahead. Should you invest $1,000 in Nvidia right now? Before you buy stock in Nvidia, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Nvidia wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $624,823!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,064,820!* Now, it's worth noting Stock Advisor's total average return is 1,019% — a market-crushing outperformance compared to 178% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025
